Two Sigma Investments LP increased its stake in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) by 94.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 199,460 shares of the biopharmaceutical company's stock after purchasing an additional 97,017 shares during the quarter. Two Sigma Investments LP owned 0.34% of Vanda Pharmaceuticals worth $955,000 as of its most recent SEC filing.
Other hedge funds have also recently modified their holdings of the company. Quantinno Capital Management LP acquired a new stake in shares of Vanda Pharmaceuticals during the fourth quarter worth $48,000. XTX Topco Ltd acquired a new stake in shares of Vanda Pharmaceuticals during the fourth quarter worth $69,000. Zacks Investment Management acquired a new stake in shares of Vanda Pharmaceuticals during the fourth quarter worth $74,000. ProShare Advisors LLC raised its position in Vanda Pharmaceuticals by 32.4% in the fourth quarter. ProShare Advisors LLC now owns 18,815 shares of the biopharmaceutical company's stock worth $90,000 after acquiring an additional 4,599 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its position in Vanda Pharmaceuticals by 17.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 22,265 shares of the biopharmaceutical company's stock worth $107,000 after acquiring an additional 3,370 shares in the last quarter. 88.14% of the stock is owned by institutional investors and hedge funds.
Insider Activity
In other news, CEO Mihael Hristos Polymeropoulos purchased 20,000 shares of the company's stock in a transaction dated Friday, May 16th. The stock was acquired at an average price of $4.22 per share, for a total transaction of $84,400.00. Following the completion of the transaction, the chief executive officer now directly owns 2,315,731 shares in the company, valued at $9,772,384.82. This represents a 0.87% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Company insiders own 10.00% of the company's stock.
Wall Street Analysts Forecast Growth
Several research firms have issued reports on VNDA. Cantor Fitzgerald reiterated an "overweight" rating and issued a $13.00 price objective on shares of Vanda Pharmaceuticals in a research report on Wednesday, May 14th. HC Wainwright reiterated a "buy" rating and issued a $20.00 price objective on shares of Vanda Pharmaceuticals in a research report on Wednesday, May 7th.
Get Our Latest Analysis on Vanda Pharmaceuticals
Vanda Pharmaceuticals Stock Performance
NASDAQ:VNDA opened at $4.61 on Friday. The stock has a fifty day moving average price of $4.29 and a two-hundred day moving average price of $4.57. The stock has a market capitalization of $271.69 million, a price-to-earnings ratio of -14.41 and a beta of 0.66. Vanda Pharmaceuticals Inc. has a 1 year low of $3.81 and a 1 year high of $6.75.
Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.05. The firm had revenue of $50.04 million during the quarter, compared to analysts' expectations of $45.13 million. Vanda Pharmaceuticals had a negative return on equity of 3.49% and a negative net margin of 9.51%. On average, analysts predict that Vanda Pharmaceuticals Inc. will post -1.12 EPS for the current year.
About Vanda Pharmaceuticals
(
Free Report)
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Vanda Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vanda Pharmaceuticals wasn't on the list.
While Vanda Pharmaceuticals currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
